Fritextsökning
Artiklar per år
Innehållstyper
-
Messa frysen om läget
Asper Systems lanserar en ny generation övervakningssystem som kan kontakta upp till fem telefonnummer om något är fel.
-
Kyla räddar nyfödda
Barn som drabbas av svår syrebrist vid förlossningen kan överleva om de får kylbehandling visar en utredning från SBU.
-
Här är kameran som du kan äta upp
På vägen genom kroppen kan den både diagnosticera och behandla svåra sjukdomar som ulcerös kolit och tjocktarmscancer. Nu lanseras det nya intelligenta kamerapillret.
-
Han är en av de främsta i världen
Till vardags är han chef vid Oslos cancerkluster. Nu tar han plats i ett av världens mest exklusiva nätverk för unga ledare, i sällskap med bland andra golfproffset Tiger Woods, Norges Kronprins Haakon och Mark Zuckerberg som grundade Facebook.
-
Nya rön kring blåbär och cancer
Möss som fick blåbärsextrakt fördubblade sin livslängd och hade hälften så stora tumörer som möss i en kontrollgrupp. Det visar en ny amerikansk studie.
-
Genmodifierad get ger medicin
Ett nytt läkemedel mot blodpropp har godkänts för försäljning i USA. Preparatet innehåller proteinet antitrombin som produceras i getter som fått en bit mänskligt DNA insatt i sina mjölkörtelceller.
-
Livsviktiga grödor ska bevaras
Regeringen har utsett SLU-forskaren som ska bli Sveriges koordinator i ett EU-program som ska rädda växter till framtiden.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
BREAKING